OncoMatch/Clinical Trials/NCT05498428
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Is NCT05498428 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for carcinoma, non-small-cell lung.
Treatment: Amivantamab · Lazertinib · Carboplatin · Pemetrexed · Direct Oral Anticoagulant (DOAC) · Low Molecular Weight Heparin (LMWH) — The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR exon 19 deletion
Required: EGFR exon 20 insertion
Required: EGFR l858r
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — locally advanced or metastatic
Cohorts 3 and 3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy.
Must have received: amivantamab + lazertinib (amivantamab, lazertinib) — locally advanced or metastatic
Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease.
Must have received: amivantamab (amivantamab)
Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction.
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California at San Diego · La Jolla, California
- University of California Irvine · Orange, California
- Stanford Cancer Institute · Stanford, California
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital · Washington D.C., District of Columbia
- Baptist Lynn Cancer Institute · Boca Raton, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify